Results 71 to 80 of about 993 (163)
Angewandte Chemie International Edition, EarlyView.Strategic incorporation of unnatural amino acids transforms macrocyclic peptides into drug‐like molecules capable of engaging challenging targets. These building blocks enhance stability, permeability, and bioavailability, accelerating the development of next‐generation peptide therapeutics.
Krishna K. Sharma +5 more
wiley +1 more source
, 2022 Rezafungin is a novel antifungal under development to become a treatment option for dealing with infectious Candida species such as the new Candida auris. However, rezafungin in vivo efficacy still was not tested against the main four clades of C. auris.
Fahami, Shiva
core
Fungal Antimicrobial Resistance: Mechanisms, Drivers, and Global Clinical Burden
ChemFoodChem, Volume 2, Issue 3, September 2026.ABSTRACT Fungal antimicrobial resistance (AMR) is a growing concern for world health caused by an increase in multidrug‐resistant infections, an increase in environmental reservoirs, and the ineffectiveness of current antifungal treatments. Fungal infections continue to be largely excluded from AMR initiatives while causing over 1.6 million deaths ...
Bikash Baral
wiley +1 more source
New Perspectives on Antimicrobial Agents: Rezafungin
Antimicrobial Agents and ChemotherapyABSTRACT Candidemia and invasive candidiasis persist as significant causes of morbidity and mortality. As fluconazole resistance rates rise, alternative means of treatment are necessary, either via mold-active azoles or extended durations of echinocandins.
Nicholas M. Forrister +2 more
openaire +2 more sources
Practices of Antifungal Prophylaxis Among Italian Pediatric Oncology–Hematology Centers
eJHaem, Volume 7, Issue 4, August 2026.ABSTRACT Background IFD is a significant cause of illness and death among pediatric patients undergoing chemotherapy or HSCT. Application of AFP in children varies widely and is frequently off‐label. This survey aims to describe real‐world AFP practices across centers within AIEOP and provide an estimate of IFD incidence.
Martina Colli +23 more
wiley +1 more source
Ex vivo Rezafungin Adsorption and Clearance During Continuous Renal Replacement Therapy
, 2018 <b><i>Background/Aims:</i></b> To determine adsorption and transmembrane clearances (CL<sub>TM</sub>) of rezafungin, a novel long-acting echinocandin, in continuous venovenous hemofiltration (CVVH).
Soo Min Jang +2 more
core +1 more source
, 2023 Background Rezafungin is a novel, once-weekly echinocandin. EUCAST rezafungin MIC testing has been associated with a good separation of WT and target gene mutant isolates in single-centre studies, but an unacceptable inter-laboratory MIC variation has ...
Zuill, Douglas E. +4 more
core +1 more source
From Oral Candidiasis to Candidemia: A Review of Superficial to Invasive Progression
MicrobiologyOpen, Volume 15, Issue 4, August 2026.Recent and limited evidence indicates that oral candidiasis can disseminate Candida albicans throughout the body, leading to invasive candidiasis, such as candidemia, a life‐threatening infection. Considering antifungal resistance and global outbreaks of emergent non‐albicans Candida and related yeasts, murine models help understand dissemination ...
Julia Robledo Jerez +3 more
wiley +1 more source
Population Pharmacokinetic Analyses for Rezafungin (CD101) Efficacy Using Phase 1 Data
, 2018 Rezafungin (CD101) is a novel echinocandin antifungal agent currently in clinical development for the treatment of candidemia and invasive candidiasis. Rezafungin has potent in vitro activity against Candida albicans
Voon Ong +3 more
core +1 more source
MicrobiologyOpen, Volume 15, Issue 1, February 2026.Essential oils with anti‐HSV‐1 activity were identified through literature review and tested against Candida to develop a formulation for co‐infections. The blend was assessed for anti‐inflammatory properties, allergenic potential via standardized BAT, and overall antiviral efficacy.
Maura Di Vito +11 more
wiley +1 more source